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Abstract 
Introduction: Head and neck cancer (HNC) is an immunosuppressive disease that demonstrates 
heterogeneous molecular characteristics and features of tumor-host interaction. Beside radiotherapy and 
surgery, the current standard of care in systemic treatment involves the use of cytotoxic chemotherapy, 
monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). There are also other modalities being 
developed under the category of immunotherapy, but they are overshadowed by the recent advancements of 
immune checkpoint inhibitors. 
Areas Covered: This systematic review covers recent advancements in “patient-specific” treatment modalities, 
which can be only administered to a given patient. 
Expert Opinion: Currently, patient-specific treatment modalities in HNC mainly consist of active immunotherapy 
using adoptive cell therapies and/or gene engineered vectors. Despite the slow pace of development, the interest 
continues in these treatment modalities.  The future of HNC treatment is expected to be guided by biomarkers 
and personalized approaches with tailored combinations of local treatments (radiotherapy, surgery), systemic 
agents and immune system modulation. Systematic research is required to generate robust data and obtain a 
high-level of evidence for the effectiveness of such treatment modalities. 
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Article Highlights 
• HNC is caused by exposure to carcinogenic substances (tobacco, alcohol, industrial chemicals) or 
oncogenic viruses (HPV, EBV) with distinct pathophysiology, biologic and immune profiles. 
• The head and neck squamous-cell carcinoma tumor microenvironment is strongly immunosuppressive 
• Currently, all patient-specific treatment modalities in HNC are under development and mainly consist of 
active immunotherapy using adoptive cell therapies and/or gene engineered vectors. 
• Despite of the emergence of advanced techniques, the current data suggest, that it is unlikely to find the 
ultimate cure for HNC using off-the-shelf or patient-specific immunotherapy in the coming years. 
• The future of HNC treatment is expected to be guided by biomarkers and personalized with tailored 
combinations of local treatments (radiotherapy, surgery), systemic agents, and modulation of patients’ 
immune system. 
• An ideal personalized and patient-specific treatment with 100% on-target action, efficacy and 
reproducibility, but 0% off-target action and toxicity is not expected in the near future. 
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1. Introduction 
With an annual incidence of 600.000 cases, head and neck cancer (HNC) is the 6th most common malignancy 
and responsible for 1-2% of all cancer deaths worldwide [1]. It is a male-predominant (75%) disease and involves 
a group of tumors arising from anatomical subsites of upper aerodigestive tract, namely nasal and paranasal 
cavities, nasopharynx, oral cavity, oropharynx, larynx, and hypopharynx. Other non-mucosal subsites of the head 
and neck are out of the scope of this article. The survival is primarily predicted by stage (lower better), 
anatomical subsite (larynx best, hypopharynx worst), and human papillomavirus (HPV) association (better if 
present). There are etiologically two distinct biological categories of HNC. The classical majority is related to 
nicotine and alcohol consumption. The second group of HNC is caused by viral infections such as oncogenic 
Human Papillomavirus (HPV) and Epstein-Barr Virus (EBV). HPV-associated HNC is often diagnosed in 
oropharynx, whereas EBV is the main cause of type II and III nasopharyngeal carcinoma. As expected, the 
molecular and immunologic characteristics of these biological entities are profoundly different from each other 
[2–6]. A wider range of mutations (e.g. TP53, CDKN2A, FAT1) characterizes the carcinogen exposure-
associated tumors, whereas the HPV and EBV-associated tumors mainly demonstrate oncoproteins expressed 
by the viral DNA integrated into the nuclei of the infected host cells. 
HNC is staged with clinical examination, multimodal imaging, pan-endoscopy and biopsies according to Union for 
International Cancer Control (UICC) system. Current standard treatment modalities in curative setting involve 
radiotherapy and/or surgery alone or in combination with cytotoxic chemotherapy agents or cetuximab, the latter 
being a mAb targeting the extracellular domain of epidermal growth factor receptor (EGFR) [7–12]. The 
recommended options for the first line systemic treatment in the recurrent and/or metastatic (R/M) setting are 
various combinations of cytotoxic chemotherapy agents and cetuximab [13,14]. The recommended second-line 
options in R/M HNC are mono-therapies with immune checkpoint inhibitors (currently, nivolumab and 
pembrolizumab are approved) [15–17], EGFR tyrosine-kinase inhibitor (TKI) afatinib [18] or combinations of 
agents used for the first-line treatment. 
Anti-Programmed Cell Death Protein 1 (PD-1)/PD-ligand (PD-L) checkpoint inhibitors, anti-EGFR mAbs and TKIs 
were not the only systemic treatment modalities under investigation in the last years. In the downstream cascade 
of EGFR pathway, mutations in PI3KCA is detected up to 35% in HNC [6]. Recently, the combination of 
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paclitaxel and the PI3K inhibitor buparlisib yielded modest but promising response rates [19]. mTOR inhibitor 
everolimus failed in two consecutive phase II trials [20,21], whereas temsirolimus, another agent from the same 
category demonstrated meaningful efficacy in another phase II trial [22]. The other downstream cascade of 
EGFR is the signal transducer and activator of transcription pathway, which is a potential target for novel small 
molecules (C188-9) and antisense oligonucleotides (AZD9150). Apart from the EGFR pathway, drugs designed 
to overcome hypoxia, induce apoptotic cancer cell death (e.g. second mitochondria-derived activator of caspase 
mimetics), inhibit other checkpoint receptors such as CTLA-4, activate co-stimulatory receptors of immune 
response (e.g. CD40, glucocorticoid-induced tumor necrosis factor receptor, toll-like receptors) and inactivate 
enzymes which deplete nutrients essential for T-cell proliferation (e.g. Indoleamine 2,3-dioxygenase, Arg1) or 
which produce toxins inhibiting T-cell proliferation (nitric oxide synthase 2, phosphodiesterase type 5), viral 
therapies and many others are under investigation [23,24]. 
The role of immunotherapy by means of the above-mentioned checkpoint inhibitors was clinically established 
within the last 2 years [15–17]. On the other hand, the term “immunotherapy” is not clearly defined, and its use is 
heavily influenced by marketing trends. At least concerning HNC, all systemic agents were labeled as 
“chemotherapy” until early 2000’s. After the publication of the IMCL-9815 [25] and EXTREME [13] trials, 
cetuximab and later other mAbs and TKIs were started to be referred as “immunotherapy” [26] or “biotherapy” 
[27], and the cytotoxic agents such as cisplatin and 5-fluoruracil remained as chemotherapeutics. With the 
establishment of anti-PD-1/PD-L immune checkpoint inhibitors and their accelerating trend, these agents took 
the role of “immunotherapy”. Ironically, the former mAbs and TKIs are now called “targeted” or “systemic” agents 
along the “chemotherapeutics”. 
The last years in oncology were marked by the success of immune checkpoint inhibitors. In line with the latest 
trend, there is a bonanza of review articles about emerging mAbs and small molecules design to modulate 
immune response to solid tumors including HNC. Of note, although being impressive compared to conventional 
therapies, around 75-80% of HNC patients do not respond to immune checkpoint inhibitors. On the other hand, 
there are also other modalities under the category of immunotherapy, which are often overlooked, despite 
continued to be developed. Therefore, we decided to check the latest literature with a different perspective, 
without the restriction of above-mentioned shifting terms. Before starting to perform this systematic review, we 
allowed ourselves to define two categories to clarify our domain of interest. Throughout this manuscript, a 
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“personalized treatment” defines a treatment, which is indicated based on a biomarker identified in an individual, 
whereas a “patient-specific” treatment designates a treatment, which can be only administered to a given patient 
and not to another person (e.g. autologous cell transplantation). Nevertheless, these terms are not mutually 
exclusive. The main focus of this systematic review is the patient-specific treatments, which emerged or 
continued to be investigated within the last five years. 
 
2.1. Methods 
An initial joint discussion between all co-authors was held, and consensus about the definitions and search terms 
was reached. The electronic search consisted of two parts: published literature and clinicaltrials.gov database. 
2.1.1. Data Extraction from Literature 
Two independent authors (OE and NC) conducted a systematic literature search in PubMed database for 
published articles between 4th of September 2013 and 4th of September 2018. The search terms implementing 
Boolean algorithms were: (“Head and Neck Neoplasms”[Mesh] NOT (“Esophageal Neoplasms”[Mesh] OR 
“Thyroid Neoplasms”[Mesh])) OR ((cancer OR carcinoma) AND ("head and neck" OR nasopharyn* OR "oral 
cavity" OR oropharyn* OR laryngeal OR larynx OR hypopharyn* OR "nasal cavity" OR sinonasal)) AND 
(“adoptive cell” OR “gene insertion” OR (“zinc finger nuclease” OR “ZFN”) OR “transcription activator-like effector 
nucleases” OR “TALENs” OR “adoptive immunotherapy” OR “cancer stem cell” OR “cancer stem cells” OR 
“tumor infiltrating lymphocytes” OR “active immunotherapy” OR “chimeric antigen receptor” OR “CAR-T” OR 
(autologous AND lymphocytes) OR (vaccine OR vaccination) OR immunotherapy OR “virus therapy” OR “viral 
therapy” OR “vector” OR “vectors” OR “clustered regularly interspaced short palindromic repeat” OR “CRISPR” 
OR “RNA interference” OR “RNAi” OR “gene edit” OR “gene editing” OR “gene therapy” OR “dendritic cell 
therapy” OR personalized OR personalised OR individualized OR individualised). PubMed categories of case 
reports and clinical study were enabled. No language restriction was applied. Additionally, meeting abstracts 
were manually searched in congress books of the American Society of Clinical Oncology, European Society of 
Medical Oncology, and European Cancer Congress between 2013 and September 2018. Reference crosscheck 
was performed in the analyzed full-text articles. Preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines [28] were followed to document details on the search strategy and selection 
processes. 
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2.1.2. Data Extraction from clinicaltrials.gov 
The XML records of all clinical trials registered at clinicaltrials.gov were downloaded on the 1st of June 2018 and 
a plain database was created to enable further analysis. The following fields were searched for head and neck 
cancer-related keywords: short title, scientific title and conditions. Systematic review of database entries was 
conducted independently by three authors (EVB, OE and NC). 
2.1.3. Eligibility Criteria 
We included publications concerning patients with HNC arising from the mucosal epithelium of nasal cavity, 
paranasal sinuses, oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. At least one of the following 
endpoints had/planned to be reported: loco-regional control, disease-free survival, progression-free survival, 
overall survival, response rate, adverse events. All studies had to be clinical and interventional involving humans.  
Extracted data were recorded into standardized spreadsheets according to the following parameters: brief name 
of the treatment under investigation (text), number of treatment cycles, biomarker selection (yes/no) patient-
specific (yes/no), mechanism of action (text) author, HNC only (yes/no), number of HNC cases in the study, 
anatomical head and neck subsites (category), disease category and treatment setting (local, locally-advanced, 
R/M), non-head and neck sites (yes/no – if yes, which), development phase (I, II, III), randomized allocation 
(yes/no), median follow-up for published data (months), response (text), grade ≥3 toxicity due to investigational 
therapy (percentage), status (published/ongoing), clinical trial ID, reference(s), remarks. Only “patient-specific” 
treatments were included in the final analysis. This term entitles a treatment which can be only administered to a 
given patient and not to another individual (e.g. autologous cell transplantation). 
 
2.2. Results 
2.2.1. Search Results 
The literature search yielded a total of 164 published articles and 8 meeting abstracts. Only 7 of those, and 1 
additional manuscript found via reference crosscheck met the eligibility criteria and were considered for detailed 
review. A flowchart detailing the number of screened, included and excluded articles, as well as the reasons for 
exclusion is provided in Figure 1. All included studies were published in the last 5 years. No articles had to be 
excluded because of language or endpoint parameters. 
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The first step of the search strategy in clinicaltrials.gov identified a total of 3950 out of 276971 trials meeting the 
keywords. Trials registered during the last five years (from 1st of June 2013 to 1st of June 2018) were selected for 
further manual review. After exclusion of prematurely terminated or those with unknown status and non-
interventional studies, 1199 trials remained for further analysis. Three hundred and fifty-eight trials did not involve 
HNC (irrelevant keyword match) and were excluded after manual review. Furthermore, trials evaluating 
therapeutic or diagnostic methods other than personalized and/or patient-specific approach were filtered out. The 
remaining entries were reviewed for the entire content. Twenty-one studies were categorized as personalized but 
not as patient-specific, and 18 as patient-specific. Figure 2 depicts the whole process with details and numbers. 
2.2.2. Names of the Therapies and Number of Cycles 
Most of the studies harness autologous cell transfer technology with various modifications. Interestingly, there is 
no naming convention even among studies using similar techniques (see the Tables 1, 2 and the section 2.2.4 
below). This may be explained by the fact that the treatments are usually not off-the shelf agents, and therefore 
not manufactured by pharmaceutical industry. The number of administered treatment cycles vary between 1 and 
6. 
2.2.3. Selection Based on Biomarker 
Two among 8 published and 5 among 17 ongoing (one completed but unpublished) trials include(d) patients 
based on the presence of biomarkers. The most common criterion was specified as the presence of human 
leukocyte antigen (HLA) phenotypes in candidates for autologous T-cell transfer. Other specified biomarkers 
were rather defined as thresholds of target antigen expression levels to be used as study inclusion criteria, such 
as EGFR, EBV copy number and Epithelial cell adhesion molecule (EpCAM). 
2.2.4. Mechanisms of Action 
In two [29,30] of the published studies, autologous monocyte-derived dendritic cells (DCs) were obtained through 
processes of apheresis, isolation, expansion and maturation with colony-stimulating factors and proinflammatory 
cytokines, and antigen-loading with specific proteins such as p53 [29] or patients’ own tumor tissue lysate [30]. 
The route of administration was either as direct injection into uninvolved (non-head and neck, such as inguinal) 
lymph nodes [29] or via intravenous [30] route. The aim/rationale was to stimulate the natural killer (NK) and T-
cells and achieve anti-tumor immune response. Both of these studies included a relatively broad spectrum of 
anatomical subsites for HNC [29] and other disease entities [30]. A similar approach seems to be adopted by 
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NCT02115958 and NCT03282617. However, these two studies explicitly focus on patients diagnosed with 
nasopharyngeal carcinoma. Another study (NCT03047525) suggests to combine autologous DCs and cytokine-
induced NK cells. However, no further detailed description in the trial registry was provided, and contact with the 
sponsor could not be established. 
In a case report, Lakota et al. [31] harvested adipose tissue-derived mesenchymal stem cells of a patient 
diagnosed with a UICC stage II squamous-cell carcinoma of the tongue, and treated them with retroviral vectors 
to transduce cytosine deaminase-uracil phosphoribosyltransferase gene to the stem cells. At the end of the 
process [32], the adipose tissue-derived mesenchymal stem cells were capable to produce the enzyme with the 
aim to reach concentrated levels of 5-fluoruracil converted from the prodrug 5-fluorocytosine in the tumor tissue. 
These stem cells are also considered to be resistant to cytotoxic chemotherapy. 
In another study by Jiang et al. [33], instead of harvesting DCs as described above, autologous T-cells were 
expanded ex vivo and stimulated with cytokines. However, the published article does not contain detailed 
information about any sensitization procedure against tumor cells. All remaining 4 published studies were 
focusing on EBV(+) nasopharyngeal carcinoma. Cytotoxic T-cells (CTLs) were selected after apheresis. 
Following stimulation and expansion, they were administered via intravenous route. In two studies [34,35], only 
EBV latent membrane protein (LMP) 2-specific CTLs targeting tumor cells were prepared. In other two studies 
[36–38], CTLs targeting a broader spectrum of antigens were utilized. Similar techniques are being used in the 
ongoing NCT02421640 and NCT02578641 studies also targeting EBV(+) nasopharyngeal carcinoma. An 
advanced version of this technique is applied in two ongoing studies. In NCT02065362, LMP/BARF1/EBNA1-
specific CTLs are produced. But additionally, these CTLs also contain retrovirus-transduced dominant gene 
receptor DNA to overcome TGF-β resistance. The same approach is being used in NCT02379520 with E6/7-
specific CTLs against HPV(+) oropharyngeal cancer. 
A different technique used in NCT03083873 involves an excisional biopsy from the R/M tumor and generation of 
its ex vivo culture. The population of tumor infiltrating lymphocytes are selectively expanded and infused back to 
the patient, followed by IL-2 administration. Instead of using DCs or CTLs, NCT02507154 harvests and re-
infuses autologous NK cells in combination of cetuximab, preceded and followed by IL-2 administration one day 
before and after in repeated cycles. This study is only recruiting patients diagnosed with R/M HNC, which exhibit 
EFGR expression above 80%. 
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Contemporary methods involve gene editing techniques such as sequence-specific RNA interference, chimeric 
antigen-expressing T-cells (CAR T-cell) therapy and clustered, regularly interspaced, short palindromic repeats – 
associated with cellular apoptotic susceptibility protein (CRISPR/Cas) [39–41]. For example, in NCT02980315 
and NCT02915445, CAR T-cells are produced to specifically bind to LMP-1 on EBV(+) nasopharyngeal 
carcinoma cells and EpCAM on head and neck and breast cancer cells, respectively. In NCT03044743, 
autologous CRISPR-Cas9 mediated PD-1 knockout EBV-antigen-specific CTLs are generated to achieve high 
on-target specificity and overcome immune blockade. Another study (NCT02989064) implementing gene editing 
is including patients diagnosed with HNC, melanoma or bladder cancer. Autologous T-cells are isolated, 
expanded and affinity-enhanced via transfusion with a lentiviral vector containing melanoma-associated gene 
(MAGE)-A10c796 T-cell receptor directed towards a MAGE-A10 peptide expressed on tumors, and re-infused into 
the subject [42]. 
Two studies aim to generate a wide spectrum of patient-specific tumor-associated antigens and stimulate host’s 
immune system via antigen presentation. NCT03265080 involves attenuated Listeria monocytogenes, which is 
specifically bioengineered to express patient-specific tumor antigens within the antigen presenting cells 
phagocytosing the bacteria. The investigators suggest that the presented antigens activate CTLs, and the 
bacterial infection itself decreases the immune-suppressing effect of Tregs and myeloid-derived suppressor cells 
in the tumor microenvironment [43]. NCT03289962 is testing the dose-limiting toxicity of RO7198457, an 
individualized mRNA compound against unique and multiple mutations identified in patients’ tumors. It is 
administered intravenously in lipoplexes by alone or with anti-PD-L1 mAb atezolizumab. 
Last but not least, innovative techniques involving the subcutaneous injection of inactivated tumor cells beside 
immune-stimulatory cells are being tested. One company is sponsoring two ongoing trials (NCT01998542, 
NCT02624999) exclusively including patients suffering from R/M HNC. A chaperone-rich tumor lysate is 
simultaneously injected with allogeneic effector T helper cells subcutaneously. Another company conducts 
NCT02999646, in which two capsules are implanted subcutaneously. One capsule contains irradiated 
autologous tumor cells. The other capsule, which is placed beside the first one, harbors genetically engineered 
allogenic cells to release Granulocyte-macrophage colony-stimulating factor as a continuous supply [44,45]. 
For further reading and detailed insight about the above-mentioned techniques, we cited some additional review 
articles [39–41,46,47] published recently. 
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2.2.5. Inclusion of Tumor Types and Anatomical Subsites 
Two published and 7 ongoing studies involve other tumor entities in addition to HNC; including urothelial 
carcinoma, colon cancer, non-small cell lung cancer, HPV-associated tumors of the anogenital region, renal-cell 
carcinoma, breast cancer, ovarian cancer, prostate cancer, sarcoma, melanoma and EBV-induced lymphoma. In 
terms of HNC, thirteen studies were designed to include nasopharyngeal carcinoma only. Ten out of these 13 
studies clearly defined the tumor of interest as EBV(+) nasopharyngeal carcinoma. Eight studies did not set any 
restriction in terms of anatomical subsite or specific histological subtype as eligibility criteria. Three studies 
allowed the non-nasopharyngeal mucosal HNC subsites, whereas 2 other studies focused on oropharyngeal 
cancer (one phase I study exclusively including HPV(+) oropharynx cancer). 
2.2.6. Treatment setting 
Three studies (Schuler et al. [29], Jiang et al. [33] and NCT02421640) were designed to include patients with 
local and locally-advanced tumors with a curative intent only. One study (NCT02115958) included HNC both in 
locally-advanced and R/M tumors with the eligibility criteria of showing clinical complete remission. Another study 
(NCT03282617) allows patients with locally-advanced and R/M disease, but allocates them into separate arms. 
However, the entry for the study NCT02980315 is missing the description of tumor stage and treatment setting in 
the clinicaltrials.gov registry. The remaining 20 studies were planned to include R/M disease only. 
2.2.7. Study Phase and Patient Allocation 
Among eight published articles, two were case reports, another two were phase I, three were phase II studies, 
and one was a phase I/II study. Unpublished studies consisted of seven phase I, three phase II, seven 
continuous phase I/II studies and one phase III study. One among published and six among ongoing studies 
were designed to allocate the patients in study arms randomly. 
2.2.8. Severe Adverse Events 
Adverse events were reported in all published studies. No grade 3 or higher toxicity was observed. 
2.2.9. Oncologic and/or Survival Outcome  
After evaluating the published studies, we decided not to describe or compare the oncologic and/or survival 
outcome in detail, mainly due to the heterogeneity in disease entities, treatment settings and reporting 
methodology of outcomes. Nevertheless, brief summaries of reported outcomes are provided in Table 1. 
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Two studies included only patients with non-metastatic local or locally-advanced HNC. However, it is not possible 
to comprehend in this setting, whether a reported oncological outcome is a result of the standard therapy or the 
following experimental treatment. Among the remaining six studies including R/M disease, none indicate a 
modality, which necessarily seems to be worth pursuing. In two of them experimenting on EBV+ nasopharyngeal 
carcinoma with autologous EBV-antigen-specific CTLs [36–38], a total of 4 out of 56 patients showed complete 
remission. But, these patients also received chemotherapy while waiting for the experimental therapy, where 
durable complete remission in selected cases with chemotherapy is not a very rare observation [48]. In earlier 
published series, durable complete responses were also reported in few patients diagnosed with R/M 
nasopharyngeal cancer [49] and other HNC subsites [50]. Similarly, most of these patients also underwent other 
conventional treatment modalities, which makes the interpretation of the results quite difficult. 
 
3. Conclusion 
Most of the identified studies involve some form of adoptive cell transfer. To our knowledge, the first studies 
involving HNC were published in 2000 and 2001 by To et al. [50], and Chua et al. [51], respectively. Both groups 
demonstrated the feasibility and a favorable safety profile in a total of 21 HNC patients, majority suffering from 
R/M disease with mixed responses. Our systematic search results indicate a continued interest in these 
treatment modalities in HNC and other solid tumors. On the other hand, the pace of research in this field is 
slower than expected. After almost two decades, most of the published and prospective studies within the last 
five years are still in the early phases of development. Due to that and heterogeneity in endpoints, investigated 
disease entities and treatment settings; it was not plausible to report and compare the outcomes between the 
published studies. Future prospective trials involving various patient-specific treatment modalities in later phases 
of development are required to generate solid data and obtain high-level of evidence for effectiveness. 
 
4. Expert Opinion 
Although being used rather vaguely, terms like personalized and precision medicine keep intriguing the public as 
well as healthcare professionals. However, concerning the treatment of cancer, the goal of a successful 
immunotherapy depicts an ideal, which has not been established so far. Modulating the immune system to defeat 
cancer is an ambitious rationale going back to the end of 19th century [52]. With the understanding of cytokines’ 
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role in immune system, researchers tried to treat malignancies with immunotherapy in a second wave in 1970s 
without achieving the expected success. The aim of immunotherapy is to re-modulate and kick-start individuals’ 
immune system to fight against their tumor and eradicate it without introducing various morbidities associated 
with surgery, radiotherapy, and systemic agents. The partial success recently demonstrated by immunotherapy 
in solid tumors including HNC is owed to the development of novel off-the-shell agents, especially those targeting 
the PD-1 receptor and PD-L1/2. According to latest data, around 75-80% of HNC patients do not profit from 
immune checkpoint inhibitors. An individualized “vaccine” approach promising major success rates in the 
treatment of solid tumors including HNC is still missing. New combinations with chemotherapy, radiotherapy, 
surgery, and agents targeting other components of immune system are being tested in loco-regional and R/M 
settings. 
Our aim before performing the systematic search was not necessarily focused on immunotherapy. However, our 
definition of patient-specific treatments yielded results, which inevitably fell into the category of immunotherapy. 
On the other hand, many off-the-shelf immunotherapy modalities were excluded. The published studies 
described in this article pursue the ideal of personalized and precision medicine for being completely 
individualized. The limited number of published studies, which involved HNC, demonstrated a favorable safety 
profile, but a modest response rate if any. The preparation phase of the treatment before administration is 
cumbersome and long, which may be shorter in the future. To bridge these delays and avoid tumor progress, 
patients in some studies are treated with cytotoxic chemotherapy, which is obviously against the notion of 
personalized and patient-specific treatments. Also, the practicality we are accustomed with the off-the-shelf 
systemic agents is lacking, which might be one of the factors holding back the investigators and the industry from 
investigation in this field. On the other hand, there seems to be a relatively week but increasing interest by the 
industry as well. Compared to the already published studies, the current proportion of ongoing industry-initiated 
projects is significantly higher.  
Outside of the field of HNC, the most remarkable example of patient-specific treatments is CAR T-cells for 
hematologic tumors, which took three decades to be developed and approved [53–55] for children and young 
adults with relapsed or refractory B-cell acute lymphoblastic leukemia [56] and refractory or relapsed adult diffuse 
large-B cell lymphoma [57]. In terms of solid tumors, other promising results with CAR T-cells and other forms of 
autologous CTLs were observed in neuroblastoma [58], melanoma and sarcoma[59]. Another success was 
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reported with an autologous DC vaccine in the treatment of prostate cancer[60]. On the other hand, reflecting the 
success of patient-specific treatments in hematologic cancers on solid tumors poses several challenges. Unlike 
the solid tumors, B-cells express CD19, which is an ideal, almost tumor-exclusive antigen to target, which allows 
specificity, therefore a wide therapeutic window. Additionally, in contrast to hematologic malignant cells, solid 
tumors usually reside in not readily-accessible sites via lympho-vascular circulation, isolated by dense stroma 
and tumor microenvironment which harbor immunosuppressive leukocytes and cytokines. Barriers against CTL 
migration also include preference to non-target organs such as lungs, liver and spleen, limited lymphocyte 
extravasation due to oncotic pressure caused by the abnormal vascular formation, downregulated expression of 
adhesion molecules on tumor vasculature and reduced release of lymphocyte-attracting chemokines. Last but 
not least, tumor heterogeneity in solid tumors poses a challenge against antigen selection. As a consequence of 
those discoveries, the following challenges need to be tackled in the future studies: off-target actions causing 
toxicity, limited lymphocyte trafficking to the tumor site(s), short persistence of the lymphocytes that arrive into 
the tumor tissue, tumor-induced immunosuppression, and the heterogeneity and ongoing evolution of multiple 
tumor-associated antigens [61]. 
A considerable number of studies addressing HNC are coming from Asia, most probably due to the endemic 
EBV+ nasopharynx cancer, which demonstrates a relatively well-defined protein expression profile. One ongoing 
trial involves a similar approach with E6 and E7-specific CTLs combined with gene editing technology to 
overcome immune-resistance. Newer studies are also more innovative by combining the patient-specific 
treatment with off-the-shelf checkpoint inhibitors with a reasonable rationale. The contemporary techniques 
integrating the gene editing techniques on immune cells or attenuated bacterial/viral vectors may offer more 
precise on-target specificity. 
In addition to develop more streamlined and faster preparation techniques, further in-depth understanding of 
tumor biology concerning driver pathways for proliferation, survival and therapy resistance, interactions with 
immune system and development in bioinformatics to tackle the mounting data output is required to achieve 
success. Solid tumors, especially HNC, harbor heterogeneous clones within the tumor, lymph nodes, and 
metastases. Current standard is to probe a part of the tumor, therefore only a part of the whole molecular 
spectrum and mutanome [62] is revealed via modern techniques. Moreover, the genetic evaluation of the tumor 
in the natural course of the disease and via selection pressures by various treatment modalities poses a 
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challenge in R/M disease. Although it is currently not easy and realistic to chase these genetic alterations over 
the course of the disease, repeated assays of circulating tumor cells and cell-free tumor DNA/RNA may offer a 
potential solution for this problem. It becomes less likely to still have one-size-fits-all treatments in the future. The 
vast possible combinations of various existing and emerging modalities, inter- as well as intra-patient 
heterogeneity in the genetic, epigenetic and immunologic landscape require smart, practical and dynamic trial 
designs. Basket [63], umbrella [64] and multi-arm, multi-stage (MAMS) [65] platform trial designs incorporating 
high-throughput diagnostic technologies may significantly increase the pace of advancement in this field. Similar 
trials testing multiple mAbs in R/M HNC recently started (e.g. NCT03088059), which prove the feasibility of such 
contemporary designs. 
Apart from the medical aspects, these modalities also have to become affordable and financially attractive for the 
public health sector and private enterprises. Last but not least, the future of the patient-specific treatments 
depends on the results the ongoing research is going to yield, as well as on the achievements in the competing 
fields of cancer research. 
Currently, it is difficult to predict any breakthrough in the near future with any given technique presented and 
discussed in this article. New generation techniques involving gene engineering and/or combination of immune 
checkpoint modulators may hold promise and should be investigated further. As demonstrated by decades of 
research and experience, it seems unlikely to find a “magic bullet” for biologically heterogeneous malignancies 
such as HNC. The future of cancer treatment is expected to be more personalized, biology-driven and involve 
tailored combinations of different treatment modalities based on patient factors, initial tumor biology, its 
interaction with the host’s immune system and their evolution through the course of the treatment. 
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5-fluoruracil converted 
from the prodrug 5-
fluorocytosine in the 
tumor tissue 
Eom et al. 
201635 
EBV-induced 
Natural T cell: 
"EBViNT" (1) 
HLA-A02+ 
or A24+ 
Autologous 
EBV/LMP2A-specific 
CTLs targeting tumor 
cells no (4) 
EBV+ 
N R/M 
lympho
ma (4) I no no NR 
Only 
descriptive 
reporting. No 
CR published 
NCT00431210 
NCT00834093 
Huang et al. 
201737 
EBV-specific 
CTL (4) no 
Autologous EBV-
antigen-specific CTLs 
targeting tumor cells 
yes 
(21) 
EBV+ 
N R/M no I/II no no NR 
Median PFS 
and OS: 2.2 
and 16.7 
months, 
respectively. 
1 CR lasting 
until last visit 
(>100 
months). 
ORR: 4.8% published 
Jiang et al. 
201533 
Cytokine-
induced killer 
cells (2) alone 
or after 1 cycle 
of docetaxel, 
cisplatin and 
5-fluoruracil no 
Expanded and 
cytokine-stimulated 
autologous T cells 
yes 
(21) OC, S 
local and 
locally-
advance
d no II no yes, but NR 48 
median PFS: 
56; OS: 58 
months 
results of 
the 
subgroup, 
which 
received 
chemother
apy 
published 
CR: complete response; CTL: cytotoxic T-cell; CUP: carcinoma of unknown primary; DC: dendritic cell; DFS: disease-free survival; EBV: Epstein-Barr virus; H: hypopharynx; HLA: human leukocyte 
antigen; HNC: head and neck cancer; L: larynx; LMP: latent membrane protein; N: nasopharynx; n: number; N/A: not available; NR: not reported; OC: oral cavity; OP: oropharynx; OS: overall survival; 
PD: progressive disease; R/M: recurrent and/or metastatic; S: sinonasal; PR: partial response; Th: T-helper cell 
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Table 2: Ongoing and Unpublished Studies in the Last Five Years 
Clinical Trial ID 
and Reference 
Name of the 
Treatment (n 
of cycles) 
Biomarker 
Selection Mechanism of Action 
HNC 
only 
(n) 
HNC 
Subsit
es 
Treatment 
Setting 
Non-HNC 
Sites 
Phas
e 
Randomi
zation Other Arms Status 
NCT01998542 
http://www.immu
novative.com/pro
ducts/allostim AlloVax™ (4) no 
AlloVax™ is Chaperone Rich cell 
lysate combined with AlloStim™ 
cells which are allogeneic Th1 
effector cells yes 
no 
restricti
on R/M no I/II yes Placebo ongoing 
NCT02065362 
TGF-β 
Resistant 
Cytotoxic T-
lymphocyte (2) no 
LMP/BARF1/EBNA1-specific 
CTLs, which also contain 
retrovirus-transduced Dominant 
Gene Receptor DNA to induce 
TGF-β resistance  yes 
EBV+ 
N R/M no I no N/A ongoing 
NCT02115958 
Cancer Stem 
Cell Vaccine 
(undetermined) no 
cancer cell antigen-loaded DC 
primed CTCs yes N 
locally advanced 
and R/M with CR no I/II yes Placebo 
completed, 
no results 
NCT02379520 
HPV-16/18 
E6/E7-Specific 
T Lymphocytes 
(in 3 sequential 
dose 
escalation 
cycles) no 
E6/7-specific CTLs, which also 
contain retrovirus-transducted 
gene to induce TGF-β resistance no 
HPV+ 
OP R/M 
HPV+ 
genitoanal I no N/A ongoing 
NCT02421640 
Concomitant 
Radiochemoth
erapy +/- tumor 
infiltrating 
lymphocytes 
(1) 
plasma 
EBV DNA 
≥4000 
copies/ml 
autologous EBV-antigen-specific 
CTLs targeting tumor cells yes 
EBV+ 
N locally advanced no II yes 
Concomitant 
radiochemotherap
y with cisplatin 
only ongoing 
NCT02507154 
autologous NK 
cells activated 
with 
Cetuximab and 
IL-2 (2) 
EGFR 
expression 
>80% 
Cetuximab and IL-2 (Day 1) and 
infusion of activated expanded 
autologous NK cells (Day 2) 
continued with additional 
Cetuximab and IL-2 infusions yes 
no 
restricti
on R/M no I/II no N/A ongoing 
NCT02578641 
Adoptive EBV-
CTL transfer 
after 4 cycles 
of gemcytabine no 
autologous EBV-antigen-specific 
CTLs targeting tumor cells yes 
EBV+ 
N R/M no III yes 
6 cycles of 
gemcitabine and 
carboplatin ongoing 
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and 
carboplatin (6) 
NCT02624999 
http://www.immu
novative.com/pro
ducts/allostim AlloVax™ (4) no 
AlloVax™ is Chaperone Rich cell 
lysate combined with AlloStim™ 
cells which are allogeneic Th1 
effector cells yes 
no 
restricti
on R/M no II yes 
6 cycles of 
cisplatin and 5-
fluoruracil ongoing 
NCT02915445 
EpCAM CAR 
T-cells (1) 
EpCAM 
>25% on 
tumor 
surface 
EpCAM CAR T-cells produced 
by lentiviral transduction no N R/M breast I no N/A ongoing 
NCT02989064 
Hong et al. 
201742 
MAGE-
A10c796T (1) 
HLA-
A*02:01+ 
and/or 
A*02:06+ 
Autologous T cells are isolated, 
expanded and affinity enhanced 
via a lentiviral vector containing 
MAGE-A10c796 T-cell receptor 
directed towards a MAGE-A10 
peptide expressed on 
tumors,and re-infused into the 
subject. no 
no 
restricti
on R/M 
bladder, 
melanoma I no N/A ongoing 
NCT02980315 
LMP-1 CAR T-
cells (1) no 
LMP-1 CAR T-cells (vector 
undefined) yes 
EBV+ 
N N/A no I/II yes placebo ongoing 
NCT02999646 
Mach et al. 
201644 
MVX-ONCO-1 
(6) no 
Subcutaneous capsule 1: 
irradiated autologous tumor cells 
4x106 
Subcutaneuous capsule 2: 
containing allogeneic cells, 
genetically engineered to release 
the strong adjuvant GM-CSF yes 
H, L, 
OC, OP R/M no I/II no N/A ongoing 
NCT03044743 
PD-1 Knockout 
EBV-CTLs (4) 
HLA-A02, 
HLA-A24 
or HLA-
A11 
CRISPR/Cas9 mediated PD-1 
knockout EBV-antigen-specific 
CTLs from autologous origin no 
EBV+ 
N R/M 
EBV+ 
lymphoma
s and 
gastric 
carcinoma I/II no N/A ongoing 
NCT03047525 
Dendritic and 
Cytokine-
induced Killer 
Cells + 
standard of 
care no no detailed description available no N R/M 
colorectal, 
lung and 
renal cell 
cancers I/II no N/A ongoing 
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chemotherapy 
(4) 
NCT03083873 
LN-145 
Autologous 
Tumor 
Infiltrating 
Lymphocytes 
(1) no 
infusion of autologous tumor 
infiltrating lymphocytes followed 
by IL-2 yes 
no 
restricti
on R/M no II no N/A ongoing 
NCT03265080 
https://www.adva
xis.com/lm-
technology-2/ 
ADXS-NEO 
(Advaxix-NEO) 
(1) no 
Bioengineered attenuated 
Listeria monocytogenes 
expresses patient-specific tumor 
antigens and that activates CTLs 
via antigen presenting cells 
phagocytosing the bacteria no 
no 
restricti
on R/M 
colon and 
lung 
cancer I no N/A ongoing 
NCT03282617 
CD137L-DC-
EBV-VAX (5-7) no 
cancer cell antigen-loaded DC 
primed CTCs yes 
EBV+ 
N 
R/M (Cohort A) or 
locally-advanced 
completed 
radiochemotherap
y no I no N/A ongoing 
NCT03289962 
https://www.canc
er.gov/publicatio
ns/dictionaries/ca
ncer-
drug/def/personal
ized-cancer-
vaccine-
ro7198457 
 
https://www.gene
.com/medical-
professionals/pip
eline 
RO7198457 
(RG6180) +/- 
Atezolizumab 
(not provided) no 
An mRNA-based individualized, 
therapeutic cancer vaccine 
targeting an unspecified number 
of tumor-associated antigens 
that are specifically expressed in 
the patient's cancer. Upon 
administration, the personalized 
cancer vaccine RO7198457 is 
taken up and translated by APCs 
and the expressed protein is 
presented via major 
histocompatibility complex 
molecules on the surface of the 
APCs. This leads to an induction 
of both CTL- and memory T-cell-
dependent immune responses no 
no 
restricti
on R/M 
multiple 
solid 
tumors I no N/A ongoing 
 
APC: antigen-presenting cells; CAR: chimeric antigen receptor; CRISPR/CAS: clustered, regularly interspaced, short palindromic repeats – associated with cellular apoptotic susceptibility protein; CTL: 
cytotoxic T-cell; DC: dendritic cell; EBV: Epstein-Barr virus; EpCAM: epithelial cell adhesion molecule; H: hypopharynx; HLA: human leukocyte antigen; HNC: head and neck cancer; HPV: Human 
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Papillomavirus; IL: interleukin; L: larynx; LMP: latent membrane protein; MAGE: Melanoma-associated gene; N: nasopharynx; n: number; N/A: not available; NK: natural killer; OC: oral cavity; OP: 
oropharynx; R/M: recurrent and/or metastatic; Th: T-helper cell 
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Figure 1: Flowchart of Literature Search 
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Figure 2: Flowchart of clinicaltrials.gov Search 
 
